Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current ratings for Taysha Gene Therapies and Artiva Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
Taysha Gene Therapies currently has a consensus price target of $12.77, indicating a potential upside of 175.79%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 471.01%. Given Artiva Biotherapeutics’ higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Taysha Gene Therapies.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | $9.77 million | 154.41 | -$109.00 million | ($0.42) | -11.02 |
| Artiva Biotherapeutics | $250,000.00 | 1,335.67 | -$83.86 million | ($3.30) | -2.07 |
Artiva Biotherapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.
Profitability
This table compares Taysha Gene Therapies and Artiva Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
Institutional & Insider Ownership
77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Taysha Gene Therapies beats Artiva Biotherapeutics on 8 of the 14 factors compared between the two stocks.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
